NB:
“Patrys has an exclusive, worldwide licence to the deoxymab technology for cancer applications from Yale University and is using this to develop and commercialise a portfolio of anti-cancer and diagnostic agents that include anti-DNA antibodies, antibody fragments, variants and conjugates. Patrys and Yale University also have filed intellectual property pertaining to the use of deoxymabs in a range of non-cancer indications, and Patrys holds the exclusive commercial rights for these opportunities.”
NB:“Patrys has an exclusive, worldwide licence to the deoxymab...
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.51M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 1.0¢ | 0.8¢ | $10.12K | 1.150M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1129 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 2085097 | 5 |
View Market Depth
| Last trade - 12.20pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
0.9¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.9¢ | 1.0¢ | 0.9¢ | 99179 | ||
| Last updated 12.20pm 30/04/2024 ? | |||||
| PAB (ASX) Chart |